875 related articles for article (PubMed ID: 34284151)
41. Superparamagnetic Iron Oxide Nanoparticles Modified with Tween 80 Pass through the Intact Blood-Brain Barrier in Rats under Magnetic Field.
Huang Y; Zhang B; Xie S; Yang B; Xu Q; Tan J
ACS Appl Mater Interfaces; 2016 May; 8(18):11336-41. PubMed ID: 27092793
[TBL] [Abstract][Full Text] [Related]
42. Selective anticancer activity of superparamagnetic iron oxide nanoparticles (SPIONs) against oral tongue cancer using in vitro methods: The key role of oxidative stress on cancerous mitochondria.
Jahanbani J; Ghotbi M; Shahsavari F; Seydi E; Rahimi S; Pourahmad J
J Biochem Mol Toxicol; 2020 Oct; 34(10):e22557. PubMed ID: 32583933
[TBL] [Abstract][Full Text] [Related]
43. Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistance.
Ming-Kun C; Zi-Xian C; Mao-Ping C; Hong C; Zhuang-Fei C; Shan-Chao Z
Cancer Commun (Lond); 2024 Feb; 44(2):205-225. PubMed ID: 38155418
[TBL] [Abstract][Full Text] [Related]
44. Extracellular Vesicle Nanoarchitectonics for Novel Drug Delivery Applications.
Sharma S; Masud MK; Kaneti YV; Rewatkar P; Koradia A; Hossain MSA; Yamauchi Y; Popat A; Salomon C
Small; 2021 Oct; 17(42):e2102220. PubMed ID: 34216426
[TBL] [Abstract][Full Text] [Related]
45. Magnetic nanoparticle-based drug delivery for cancer therapy.
Tietze R; Zaloga J; Unterweger H; Lyer S; Friedrich RP; Janko C; Pöttler M; Dürr S; Alexiou C
Biochem Biophys Res Commun; 2015 Dec; 468(3):463-70. PubMed ID: 26271592
[TBL] [Abstract][Full Text] [Related]
46. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source.
Meng W; He C; Hao Y; Wang L; Li L; Zhu G
Drug Deliv; 2020 Dec; 27(1):585-598. PubMed ID: 32264719
[TBL] [Abstract][Full Text] [Related]
47. Extracellular Vesicle Production Loaded with Nanoparticles and Drugs in a Trade-off between Loading, Yield and Purity: Towards a Personalized Drug Delivery System.
Piffoux M; Silva AKA; Lugagne JB; Hersen P; Wilhelm C; Gazeau F
Adv Biosyst; 2017 May; 1(5):e1700044. PubMed ID: 32646153
[TBL] [Abstract][Full Text] [Related]
48. Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy.
Jayasinghe MK; Pirisinu M; Yang Y; Peng B; Pham TT; Lee CY; Tan M; Vu LT; Dang XT; Pham TC; Chen H; Leung AYH; Cho WC; Shi J; Le MT
Theranostics; 2022; 12(7):3288-3315. PubMed ID: 35547755
[TBL] [Abstract][Full Text] [Related]
49. Phosphocholine-decorated superparamagnetic iron oxide nanoparticles: defining the structure and probing in vivo applications.
Luchini A; Irace C; Santamaria R; Montesarchio D; Heenan RK; Szekely N; Flori A; Menichetti L; Paduano L
Nanoscale; 2016 May; 8(19):10078-86. PubMed ID: 26751053
[TBL] [Abstract][Full Text] [Related]
50. Magnetically Enhanced Intracellular Uptake of Superparamagnetic Iron Oxide Nanoparticles for Antitumor Therapy.
Choi J; Kim DI; Kim JY; Pané S; Nelson BJ; Chang YT; Choi H
ACS Nano; 2023 Aug; 17(16):15857-15870. PubMed ID: 37477428
[TBL] [Abstract][Full Text] [Related]
51. Glioma-targeted superparamagnetic iron oxide nanoparticles as drug-carrying vehicles for theranostic effects.
Xu HL; Mao KL; Huang YP; Yang JJ; Xu J; Chen PP; Fan ZL; Zou S; Gao ZZ; Yin JY; Xiao J; Lu CT; Zhang BL; Zhao YZ
Nanoscale; 2016 Aug; 8(29):14222-36. PubMed ID: 27396404
[TBL] [Abstract][Full Text] [Related]
52. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases.
Leuschner C; Kumar CS; Hansel W; Soboyejo W; Zhou J; Hormes J
Breast Cancer Res Treat; 2006 Sep; 99(2):163-76. PubMed ID: 16752077
[TBL] [Abstract][Full Text] [Related]
53. Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery.
Mohammadi AH; Ghazvinian Z; Bagheri F; Harada M; Baghaei K
BioDrugs; 2023 May; 37(3):353-374. PubMed ID: 37093521
[TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo experiments with iron oxide nanoparticles functionalized with DEXTRAN or polyethylene glycol for medical applications: magnetic targeting.
Mojica Pisciotti ML; Lima E; Vasquez Mansilla M; Tognoli VE; Troiani HE; Pasa AA; Creczynski-Pasa TB; Silva AH; Gurman P; Colombo L; Goya GF; Lamagna A; Zysler RD
J Biomed Mater Res B Appl Biomater; 2014 May; 102(4):860-8. PubMed ID: 24458920
[TBL] [Abstract][Full Text] [Related]
55. Extracellular Vesicles in the Development of Cancer Therapeutics.
Sun H; Burrola S; Wu J; Ding WQ
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847103
[TBL] [Abstract][Full Text] [Related]
56. Cancer Therapy Empowered by Extracellular Vesicle-Mediated Targeted Delivery.
Chen Y; Huang Y; Deng Y; Liu X; Ye J; Li Q; Luo Y; Lin Y; Liang R; Wei J; Zhang J; Li Y
Biol Pharm Bull; 2023; 46(10):1353-1364. PubMed ID: 37779037
[TBL] [Abstract][Full Text] [Related]
57. Recent Progress in Iron Oxide Nanoparticles as Therapeutic Magnetic Agents for Cancer Treatment and Tissue Engineering.
Nabavinia M; Beltran-Huarac J
ACS Appl Bio Mater; 2020 Dec; 3(12):8172-8187. PubMed ID: 35019598
[TBL] [Abstract][Full Text] [Related]
58. Uremic Toxin-Induced Exosome-like Extracellular Vesicles Contain Enhanced Levels of Sulfated Glycosaminoglycans which Facilitate the Interaction with Very Small Superparamagnetic Iron Oxide Particles.
Freise C; Zappe A; Löwa N; Schnorr J; Pagel K; Wiekhorst F; Taupitz M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762555
[TBL] [Abstract][Full Text] [Related]
59. Bioactivity of Hybrid Polymeric Magnetic Nanoparticles and Their Applications in Drug Delivery.
Mohammed L; Ragab D; Gomaa H
Curr Pharm Des; 2016; 22(22):3332-52. PubMed ID: 26853596
[TBL] [Abstract][Full Text] [Related]
60. Extracellular Vesicles for Immunomodulation in Tissue Regeneration.
Zhang K; Liu L; Shi K; Zhang K; Zheng C; Jin Y
Tissue Eng Part C Methods; 2022 Aug; 28(8):393-404. PubMed ID: 35856810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
